EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 86 filers reported holding EDGEWISE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 3.56 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $45 | +25.0% | 2,512 | +29.0% | 0.00% | – |
| Q1 2024 | $36 | -7.7% | 1,947 | -45.1% | 0.00% | – |
| Q4 2023 | $39 | +69.6% | 3,547 | -10.0% | 0.00% | – |
| Q3 2023 | $23 | -25.8% | 3,943 | 0.0% | 0.00% | – |
| Q2 2023 | $31 | +19.2% | 3,943 | 0.0% | 0.00% | – |
| Q1 2023 | $26 | -40.9% | 3,943 | -20.1% | 0.00% | – |
| Q4 2022 | $44 | -99.9% | 4,936 | +18.8% | 0.00% | – |
| Q3 2022 | $41,000 | +24.2% | 4,154 | 0.0% | 0.00% | – |
| Q2 2022 | $33,000 | -45.9% | 4,154 | -34.1% | 0.00% | – |
| Q1 2022 | $61,000 | – | 6,299 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |